Combating resistant pathogens: exploring the efficacy of eravacycline utilization in multidrug-resistant infections

The increasing prevalence of multidrug-resistant infections, including carbapenem-resistant Enterobacterales and vancomycin-resistant Enterococcus, has made successful treatment of infections due to these organisms challenging. This study contributes to the growing body of literature on the use of eravacycline for multidrug-resistant infections, offering evidence of its safety and efficacy in this context. However, current guidelines do not widely endorse the use of eravacycline due to limited data despite its potential advantages. Many guideline-recommended treatments for these organisms have significant drawbacks, including substantial toxicity, collateral damage such as resistance selection, increased risk of <i>Clostridioides difficile</i> infection, and higher healthcare costs. Eravacycline may serve as a valuable salvage therapy in such scenarios due to its broad-spectrum activity and lower <i>Clostridioides difficile</i> risk. As resistance patterns evolve, eravacycline's broad-spectrum activity may become a more used option in the management of difficult-to-treat infections, expanding therapeutic options for patients with few viable antimicrobial therapies.